Welcome to our dedicated page for 20/20 Biolabs SEC filings (Ticker: AIDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on 20/20 Biolabs's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into 20/20 Biolabs's regulatory disclosures and financial reporting.
20/20 Biolabs, Inc. ownership filing: Streeterville Capital LLC reports beneficial ownership of 543,680 shares, representing 9.99% of the company's common stock. The filing cites 5,442,249 shares outstanding as of February 18, 2026 and attributes the position to warrants and Series E convertible preferred rights subject to a contractual 9.99% ownership cap.
The report is filed by Streeterville Capital LLC, Streeterville Management LLC, and John M. Fife, who is identified as manager/sole member; voting and dispositive power is reported as sole for 543,680 shares.
20/20 Biolabs, Inc. director John Woodson Rollins reported automatic conversions of preferred stock into common shares. On February 19, 2026, 13,029 shares of Series A preferred and 6,135 shares of Series A-2 preferred were converted into an equivalent number of common shares upon the listing of the company’s common stock on the Nasdaq Capital Market. After these derivative conversions, he held 30,275 shares of common stock directly.
20/20 Biolabs, Inc. director Michael A. Ross reported an automatic conversion of preferred stock into common stock tied to the company’s listing on the Nasdaq Capital Market. On February 19, 2026, all 31 shares of Series A-2 preferred stock he held converted into 31 shares of common stock at no stated cost, leaving him with 31 common shares held directly and no remaining Series A-2 preferred shares.
20/20 Biolabs, Inc. director John G. Compton reported an automatic conversion of preferred stock into common stock. On February 19, 2026, 7,669 shares of Series A-2 preferred stock converted into 7,669 shares of common stock at a stated price of $0.00 per share upon the listing of the company’s common stock on the Nasdaq Capital Market. After this derivative conversion, Compton directly held 14,335 shares of common stock.
20/20 Biolabs, Inc. director Richard M. Cohen acquired 7,700 shares of common stock through the conversion of preferred stock. On February 19, 2026, all 7,700 shares of Series A-2 preferred stock he held automatically converted into an equivalent number of common shares when the company’s common stock listed on the Nasdaq Capital Market. Following the transaction, he directly held 7,700 common shares and no Series A-2 preferred shares. This was a non-cash derivative conversion, not an open-market purchase.
20/20 Biolabs, Inc. director John Woodson Rollins filed an initial ownership report showing direct holdings of several equity instruments in AIDX. He reports 13,029 shares of Series A Preferred Stock and 6,135 shares of Series A-2 Preferred Stock, each convertible into common stock on a one-for-one basis at his option and automatically if the common stock lists on a national exchange. He also holds multiple stock options, including grants for 48,780, 76,628, 37,584, 37,583, 30,000 and 30,000 shares of common stock, with vesting terms described in the notes, and 11,111 shares of common stock directly owned. The filing records existing positions rather than new purchases or sales.
20/20 Biolabs, Inc. filed Amendment No. 2 to its Form S-1 registration statement. This amendment is technical in nature and is being used primarily to file and organize exhibits listed in Item 16, such as charter documents, warrants, financing agreements, license agreements, and director and officer contracts.
The company states that the preliminary prospectus in Part I and the rest of Part II of the original registration statement remain unchanged and are omitted from this amendment. The filing also includes standard SEC undertakings about future post-effective amendments, liability, and indemnification, and is signed by Chief Executive Officer Jonathan Cohen and the company’s directors.